Decoy Therapeutics Inc.
Decoy Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule cancer therapies for tumors driven by dysregulated gene expression. Its pipeline centers on two programs, SP-3164 and seclidemstat (SP-2577), which are designed to address high unmet medical need in both liquid and solid tumors.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSmall-molecule drugs designed to degrade disease-driving proteins in cancer cells.
Small-molecule inhibitors intended to block dysregulated protein activity in oncology.
Computational and experimental tools used to identify and optimize new drug candidates.
Out-licensing or collaboration structures used to advance assets and fund development.
Customers
Decoy does not yet sell approved products, so its near-term 'customers' are primarily potential pharmaceutical partners, investors, and eventually oncology physicians and healthcare systems if any candidate is commercialized. In the current stage, value is created by advancing drug candidates through preclinical and clinical development and by securing collaborations that can fund or de-risk commercialization.
Potential collaborators or licensees that may fund development, share risk, or commercialize Decoy's assets.
Future end users of approved therapies for cancers with high unmet medical need.
Insurers and government programs that would reimburse treatment if products are approved.
Equity investors and financing counterparties that fund operations before commercialization.
Strategy
Decoy's strategy is to advance its oncology pipeline while preserving capital through cost reductions, partnerships, and selective use of external resources. The company is also pursuing strategic alternatives and merger-related actions, reflecting a focus on maximizing stockholder value while trying to keep development optionality alive.
The company has no product revenue and limited cash, so survival depends on reducing burn and raising capital.
Pipeline progress is the main driver of value before any commercialization can occur.
External capital and partner capabilities are needed to fund development and future commercialization.
Geography
Decoy is headquartered in Houston, Texas and currently operates as a U.S.-based development-stage company. Its commercial exposure is still largely theoretical because it has no approved products, but any future launch would likely require U.S. commercialization capabilities and, potentially, ex-U.S. partners for broader reach.
Risks
Decoy is a pre-revenue biotech with substantial going-concern risk, meaning its ability to continue operations depends on raising additional capital. Its business also depends on successful preclinical/clinical execution, regulatory approval, third-party manufacturing, and the retention of a small number of key executives and scientists.
- Going-concern and financing riskImpact: CriticalLikelihood: High
The company has no product sales, limited cash, and expects continued losses, so it must raise capital to survive.
Exposure: Operations may cease without new funding
- Clinical development failureImpact: HighLikelihood: High
Pipeline value depends on identifying, validating, and advancing drug candidates through trials.
Exposure: SP-3164 and seclidemstat
- Regulatory approval riskImpact: HighLikelihood: High
Even promising candidates require FDA approval and may need additional studies or trials.
Exposure: Future oncology product candidates
- Third-party manufacturing and trial execution riskImpact: HighLikelihood: Medium
Decoy relies on external manufacturers and clinical service providers, creating supply and quality risks.
Exposure - Key-person riskImpact: MediumLikelihood: Medium
The company is highly dependent on a small set of executives and scientific leaders.
Exposure
Accounting
Judgemental itemsOutsourced research, manufacturing, and laboratory costs are expensed as incurred and can swing with trial activity.
Impact: Affects operating loss and comparability across periods
Professional fees and integration-related expenses can be material during restructuring or merger periods.
Impact: Can temporarily inflate G&A expense
Higher accrued expenses can reduce current-period cash outflow without changing expense recognition.
Impact: Affects operating cash flow versus earnings
Limited cash and recurring losses require explicit disclosure of funding uncertainty.
Impact: Important for assessing solvency and liquidity
Similar listed companies
Publicly listed companies with a comparable business focus.
Prelude Therapeutics Inc
PRLD · Pharmaceutical Preparations
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Transcode Therapeutics, Inc.
RNAZ · Pharmaceutical Preparations
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026